BioSpace1h
Emalex Heads to FDA After Phase III Tourette Syndrome Win
In the Phase III trial, 41.9% of pediatric Tourette syndrome patients relapsed after ecopipam treatment, as compared with ...
ENDPOINTS NEWS18h
Chica­go biotech Emalex says it cleared a Phase 3 for Tourette syn­drome, will seek FDA ap­proval
Emalex Biosciences said its daily oral tablet helped reduce relapses for children and adults with Tourette syndrome in a ...
FierceBiotech21h
Emalex dopamine blocker stops Tourette syndrome relapse in phase 3 win
Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrome relapsing in a phase 3 trial, setting the ...
Le Lézard23h
Board-Certified Physicians Celia Garner, MD, and Nicholas G. Hanson, MD, Open MDVIP-Affiliated Practices in Salt Lake City
MDVIP, the market leader in membership-based healthcare with a network of over 1,300 primary care physicians nationwide, has ...
Le Lézard23h
Drone Detection Market worth $2,329.9 million by 2029 - Exclusive Report by MarketsandMarketstm
The Drone detection market is estimated in terms of market size to be USD 659.4 million in 2024 to USD 2,329.9 million by 2029, at a CAGR of 28.7% according to a new report by MarketsandMarketstm. The ...
Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study
Emalex Biosciences met primary and secondary endpoints in its Phase 3 registrational trial of ecopipam for patients with ...